NICE Endorses Natalizumab RRMS Treatment Expans...

By João L. Carapinha

January 9, 2026

NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases The National Institute for Health and Care Excellence (NICE) has issued final draft ...
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
Novartis Drug Pricing Agreement
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity
Africa Medicine Roadmap: Paving the Way for Sustainable Access to Quality Pha...
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Preparing for the EU Health Technology Assessment: Key Insights from the Upco...
Transforming EU Pharmaceutical Legislation: EMA’s Strategic Priorities ...
Strategic Avalere Health Appointments Enhance Leadership in Navigating US Hea...
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...